ArticleBMJ open ophthalmology2019
Dispersive viscosurgical devices demonstrate greater efficacy in protecting corneal endothelium in vitro.
Article in BMJ open ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Hyaluronic acid concentration predictably modulates physicochemical properties and clinical performance in ophthalmic viscosurgical devices: integrated laboratory and prospective clinical assessment.BMC ophthalmology · 2026Trial
- The soft-shell technique in eyes with a shallow anterior chamber - a randomized trial on the influence of the ophthalmic viscosurgical device.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Trial
- Intracameral pressure during capsulorhexis in cataract surgery using cohesive versus dispersive ophthalmic viscosurgical devices: a randomised trial.BMJ open ophthalmology · 2026Trial
- Corneal endothelial cell loss and intraocular pressure following phacoemulsification using a new viscous-cohesive ophthalmic viscosurgical device.International ophthalmology · 2024Trial
- Safety and Efficacy of Eyevisc™ 2.4% Ophthalmic Viscosurgical Device in Cataract Surgery.Cureus · 2026Article
- Evaluation of a Modified Single-Stage Continuous Curvilinear Capsulorhexis Technique Using 18-Gauge Needle Decompression in Intumescent Cataracts.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Intraocular pressure before and after capsulorhexis using two viscoelastic substances and two surgical approaches in enucleated porcine eyes.International journal of ophthalmology · 2024Article
- Temperature Change of Ophthalmic Viscosurgical Devices in a Bi-Chamber Set-Up at a Flow of 0 and 20mL/min.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Ophthalmic viscosurgical device interaction with two hydrophobic acrylic intraocular lenses of different equilibrium water content.Scientific reports · 2022Article
- Risk factors for fluctuations in corneal endothelial cell density (Review).Experimental and therapeutic medicine · 2022Review
- Ophthalmic Viscosurgical Devices (OVDs) in Challenging Cases: a Review.Ophthalmology and therapy · 2021Review
- Modified capsulorhexis for fiuid-filled mature cataracts.Medical hypothesis, discovery & innovation ophthalmology journal · 2021Article
- Evaluation of femtosecond laser-assisted anterior capsulotomy in the presence of ophthalmic viscoelastic devices (OVDs).Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDuring phacoemulsification, the corneal endothelium is protected by an ophthalmic viscosurgical device (OVD). In this in vitro study, we assessed six different OVDs for their effectiveness in protecting the corneal endothelium. METHODS AND ANALYSIS: Phacoemulsification was performed in cadaver eyes of young pigs. Five syringe units of six different OVDs were tested (Healon EndoCoat, Viscoat, Methylvisc, Healon, Healon GV, ProVisc). After surgery, the area of endothelium coated with OVD was determined in relation to the total endothelial surface. Additionally, an endothelial cell count was obtained. As a control, an endothelial cell count was obtained from freshly trephined corneas. Statistical analysis was performed using the Mann-Whitney U test and the Spearman correlation.
resultsThe least postoperative endothelial coating and cell count were observed in the cohesive OVDs while the dispersive OVDs showed statistically significant higher values. Healon EndoCoat and Viscoat yielded a coating area of 86 (85-92)% and 85 (85-90)%, respectively. Endothelial cell count was highest in the two dispersive groups with 4065 (3928-4088) cells/mm
conclusionDispersive OVDs from this study showed greater adherence to the endothelial surface than the cohesive ones. Furthermore, postoperative endothelial cell counts of corneas treated with dispersive OVDs were higher than of corneas treated with cohesive OVDs. Our in vitro results suggest that dispersive OVDs protect the corneal endothelium better during phacoemulsification than cohesive OVDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.